Background: Candida species are the third most common cause of pediatric health care–associated bloodstream infection in the United States and Europe. To our knowledge, this report from the ...
Background: Invasive candidiasis is an increasing problem in neonatal intensive care units worldwide and is an important cause of morbidity, mortality and prolongation of hospital stay. Despite ...
Invasive candidiasis, which in many patients represents a life-threatening condition, is “largely a disease of medical progress,” according to the Guidelines. Risk factors include the use of ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO ® ...
ReSTORE trial met both primary endpoints and demonstrated non-inferiority of rezafungin versus current standard of care, caspofungin1 Rezafungin demonstrated high mycological efficacy rates in initial ...
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients ...
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – ...
Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews. 2007;20 (1),133-163. 10 Parkins MD, Sabuda DM, Elsayed S, et al. Adequacy of empirical ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC today announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candidiasis in adults ...
Study finds that mesalamine, a common anti-inflammatory drug, can fight the fungus Candida albicans in the gut, potentially preventing the risk of invasive candidiasis in patients with blood cancers.
Credit: Melinta Therapeutics. Rezzayo is supplied as a solid (cake or powder) in a single-dose vial containing 200mg of rezafungin. Rezzayo ™ (rezafungin for injection) is now available for the ...
Please provide your email address to receive an email when new articles are posted on . Among patients with IFI, yeast on donor culture and prolonged length of stay were associated with early IC risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results